Overview

Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors

Status:
Recruiting

Trial end date:
2020-12-31

Target enrollment:

Participant gender:

Summary

To explore the safety and efficacy of Glumetinib combined with Osimertinib in the treatment of relapsed and metastatic non-small cell lung cancer (NSCLC) with failed first-generation or second-generation EGFR inhibitors, negative T790M mutation and met amplification.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Haihe Biopharma Co., Ltd.
ShangHai HaiHe Pharmaceutical

Treatments:

Osimertinib